Literature DB >> 10576390

Long-term effects of distal splenorenal shunt with splenopancreatic and gastric disconnection on hypersplenism due to liver cirrhosis.

H Miura1, S Kondo, T Shimada, H Sugiura, T Morikawa, S Okushiba, H Katoh.   

Abstract

BACKGROUND/AIMS: Though the distal splenorenal shunt has been applied for gastroesophageal varices caused by liver cirrhosis, many patients develop secondary hypersplenism due to the portal hypertension following liver cirrhosis. We examined whether this operation could be effective for alleviating secondary hypersplenism for a long post-operative period. The subjects were 42 cases with gastroesophageal varices following liver cirrhosis in which we had performed distal splenorenal shunts with splenopancreatic and gastric disconnection at our institution in the period from 1983 1994 and the post-operative survival periods had been over 3 years.
METHODOLOGY: White blood cell counts, platelet counts and spleen volume were measured prior to operation, 1 month after operation and during the post-operative period of 3-5 years. Quality of life and clinical symptoms were evaluated during the post-operative period of 3-5 years.
RESULTS: White blood cell counts, platelet counts and spleen volume were improved respectively at 1 month and during the 3-5-year period after surgery, compared to those prior to operation. None of the clinical symptoms of hypersplenism were observed and the long-term performance status was satisfactory.
CONCLUSIONS: We can conclude that the distal splenorenal shunt with splenopancreatic and gastric disconnection alleviated hypersplenism for post-operatively long periods.

Entities:  

Mesh:

Year:  1999        PMID: 10576390

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  2 in total

1.  Long-term efficacy of distal splenorenal shunt with splenopancreatic and gastric disconnection for esophagogastric varices in patients with idiopathic portal hypertension.

Authors:  Ryunosuke Hase; Satoshi Hirano; Satoshi Kondo; Shunichi Okushiba; Toshiaki Morikawa; Hiroyuki Katoh
Journal:  World J Surg       Date:  2005-08       Impact factor: 3.352

2.  Coated transjugular intrahepatic portosystemic shunt does not improve thrombocytopenia in patients with liver cirrhosis.

Authors:  Elise J Barney; Ester C Little; Richard D Gerkin; Alberto X Ramos; Jeffrey Kahn; Mark Wong; Geetha Kolli; Richard Manch
Journal:  Dig Dis Sci       Date:  2012-05-16       Impact factor: 3.199

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.